(Press-News.org) In a small trial, Mass General Brigham researchers found a drug designed to treat Celiac disease supported a more rapid return to normal activities for patients following COVID.
Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition that can occur after a COVID-19 infection, presenting as high fevers, gastrointestinal symptoms, and life-threatening cardiac injury. A small, randomized clinical trial led by Mass General Brigham investigators found the oral drug larazotide—an experimental drug originally designed to treat Celiac disease—was both safe and effective in treating children with MIS-C. Their results are published in Science Translational Medicine.
“While our study is small, its results are powerful and have implications not only for MIS-C, but potentially for long COVID,” said lead author Lael Yonker, MD, co-director of the Cystic Fibrosis Center, Cystic Fibrosis Therapeutic Development Center, and Pulmonary Genetics Clinic at Mass General Brigham for Children. “Our findings suggest that larazotide is safe and quickly resolves symptoms in children with MIS-C. We are now running a clinical trial to test whether larazotide may also be a useful therapy to treat patients with long COVID.”
Current MIS-C treatments are limited. Some patients receive general anti-inflammatory drugs, but many experience a rebound of symptoms after completing a course. Such drugs are not designed to target the sticky SARS-CoV-2 viral particles that may persist in the gut. Enter larazotide, an orally administered drug that does target the gut. Larazotide strengthens intestinal barriers to limit the number of materials—like SARS-CoV-2 viral particles—that exit the intestines and enter circulation.
To test larazotide’s efficacy and safety as an MIS-C treatment, researchers conducted a double-blind clinical trial with 12 children experiencing early-stage MIS-C. The study was funded in part by the National Institutes of Health. Each patient randomly received either a placebo or larazotide four times daily for 21 days, then was tracked over six months of recovery. Children who received larazotide showed faster resolution of gastrointestinal symptoms, faster clearance of SARS-CoV-2 viral particles, and more rapid return to normal activities. The findings demonstrate larazotide may be a safe and promising treatment option for children with MIS-C.
Authorship: In addition to Yonker, Mass General Brigham authors include Abigail S. Kane, Zoe Swank, Lena Papadakis, Victoria Kenyon, Samuel Han. Rosiane Lima, Lauren B. Guthrie, Bryan Alvarez-Carcamo, Manuella Lahoud-Rahme, Duraisamy Balaguru, Ryan W. Carroll, Josephine Lok, Chadi El Saleeby, David R. Walt, and Alessio Fasano.
Disclosures: Fasano is cofounder and stockholder of Alba Therapeutics and is currently Chief Science and Medical Officer at Mead Johnson Nutrition. Walt has a financial interest in Quanterix Corporation, a company that developed an ultrasensitive digital immunoassay platform; he is an inventor of the Simoa technology, a founder of the company and also serves on its board of directors. Yonker, Walt, and Fasano are coinventors on a patent no. PCT/IB2022/052764 entitled “Zonulin antagonists for the treatment of multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A)”.
END
Clinical trial finds safe, effective treatment for children with severe post-Covid syndrome
2025-07-30
ELSE PRESS RELEASES FROM THIS DATE:
Researchers map where solar energy delivers the biggest climate payoff
2025-07-30
Increasing solar power generation in the United States by 15% could lead to an annual reduction of 8.54 million metric tons of carbon dioxide emissions, according to researchers at Rutgers, the Harvard T.H. Chan School of Public Health and Stony Brook University.
The study, published in Science Advances, found that the climate benefits of solar power differ markedly throughout U.S. regions, pinpointing where clean energy investments return the greatest climate dividends.
In 2023, 60% of U.S. electricity generation relied on fossil fuels, while 3.9% came from solar, according to the U.S. Energy Information ...
Carbon fiber boosts dry-processed battery performance
2025-07-30
Oak Ridge National Laboratory (ORNL) researchers have overcome a barrier to using a more affordable, dry process for manufacturing the lithium-ion batteries used in vehicles and electronic devices. The resulting batteries provide greater electricity flow and reduced risk of overheating.
Dry processing is a method for making electrode films that eliminates the need for wet organic solvents that require increased factory floor space, time, energy, waste disposal and startup expenses. However, dry-processed films tear easily. To address this issue, ORNL researchers incorporated long carbon fibers, then tested coin cell batteries made from ...
Influenza-associated acute necrotizing encephalopathy in US children
2025-07-30
About The Study: In this case series of children with influenza-associated acute necrotizing encephalopathy from the 2 most recent influenza seasons in the U.S., the condition was associated with high morbidity and mortality in this cohort of predominantly young and previously healthy children. The findings emphasize the need for prevention, early recognition, intensive treatment, and standardized management protocols.
Corresponding Author: To contact the corresponding author, Andrew Silverman, MD, MHS, email Aesilver@stanford.edu.
To access the embargoed study: Visit ...
Rainy tropics could face unprecedented droughts as an Atlantic current slows
2025-07-30
Some of the rainiest places on Earth could see their annual precipitation nearly halved if climate change continues to alter the way ocean water moves around the globe.
In a new CU Boulder-led study published July 30 in Nature, scientists revealed that even a modest slowdown of a major Atlantic Ocean current could dry out rainforests, threaten vulnerable ecosystems and upend livelihoods across the tropics.
“That’s a stunning risk we now understand much better,” said lead author Pedro DiNezio, associate professor in CU Boulder’s Department of Atmospheric and Oceanic Sciences, adding that parts of the Amazon rainforest could see up to a 40% reduction ...
‘One and done’: A single shot at birth may shield children from HIV for years, study finds
2025-07-30
A new study in Nature shows that delivering a single injection of gene therapy at birth may offer years-long protection against HIV, tapping into a critical window in early life that could reshape the fight against pediatric infections in high-risk regions.
This study is among the first to show that the first weeks of life, when the immune system is naturally more tolerant, may be the optimal window for delivering gene therapies that would otherwise be rejected at older ages.
“Nearly ...
New method for detecting neutrinos
2025-07-30
Neutrinos are extremely elusive elementary particles. Day and night, 60 billion of them stream from the Sun through every square centimeter of the Earth every second, which is transparent to them. After the first theoretical prediction of their existence, decades passed before they were actually detected. These experiments are usually extremely large to account for the very weak interaction of neutrinos with matter. Scientists at the Max Planck Institute for Nuclear Physics (MPIK) in Heidelberg have now succeeded in detecting antineutrinos from the reactor of a nuclear power plant using the CONUS+ experiment, with a detector mass of just ...
Respiratory viruses can wake up breast cancer cells in lungs
2025-07-30
JULY 30, 2025—Researchers at the University of Colorado Anschutz Medical Campus, Montefiore Einstein Comprehensive Cancer Center (MECCC), and Utrecht University have found the first direct evidence that common respiratory infections, including COVID-19 and influenza, can awaken dormant breast cancer cells that have spread to the lungs, setting the stage for new metastatic tumors. The findings published today in Nature, obtained in mice, were supported by research showing increases in death and in metastatic lung disease among cancer survivors infected with SARS-CoV-2, the virus that causes COVID-19.
“Our findings indicate that individuals with a history of ...
Stroke center certification and within-hospital racial disparities in treatment
2025-07-30
About The Study: In this cohort study, the likelihood of receiving stroke treatments increased for white but not Black patients within the same facility after the center was stroke certified as a primary stroke center or a thrombectomy-capable or comprehensive stroke center. These within-hospital racial differences serve as sobering evidence that racial disparities in stroke care persist despite increased access to care.
Corresponding Author: To contact the corresponding author, Renee Y. Hsia, MD, MSc, email renee.hsia@ucsf.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.24027)
Editor’s ...
Mortality among surgeons in the United States
2025-07-30
About The Study: Although nonsurgeon physicians have lower mortality rates than other highly educated professionals, this mortality benefit does not extend to surgeons. Because surgeons and nonsurgeon physicians have similar levels of health care knowledge and resources, higher mortality rates among surgeons might reflect differences related to work environment, professional demands, and lifestyle. The results of this study indicate that several causes of death (e.g., motor vehicle collisions), disproportionately affect surgeons, aligning ...
Carbon 'offsets' aren't working. Here's a way to improve nature-based climate solutions
2025-07-30
A lot of the climate-altering carbon pollution we humans release into the atmosphere by burning fossil fuels gets drawn into Earth’s oceans and landscapes through natural processes, mostly through photosynthesis as plants turn atmospheric carbon dioxide into biomass.
Efforts to slow the climate crisis have long sought to harness nature, often through carbon “offsets,” aimed at bolstering forests, wetlands, and agriculture, but have generally had only marginal success so far.
A new approach: contributions ...